[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse PDP1

Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix
Domain PF00481 Protein phosphatase 2C
Function

Catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex.

> Gene Ontology
 
Biological Process GO:0006084 acetyl-CoA metabolic process
GO:0006085 acetyl-CoA biosynthetic process
GO:0006086 acetyl-CoA biosynthetic process from pyruvate
GO:0006090 pyruvate metabolic process
GO:0006470 protein dephosphorylation
GO:0006631 fatty acid metabolic process
GO:0006637 acyl-CoA metabolic process
GO:0006732 coenzyme metabolic process
GO:0006790 sulfur compound metabolic process
GO:0009108 coenzyme biosynthetic process
GO:0010510 regulation of acetyl-CoA biosynthetic process from pyruvate
GO:0010565 regulation of cellular ketone metabolic process
GO:0016311 dephosphorylation
GO:0019216 regulation of lipid metabolic process
GO:0019217 regulation of fatty acid metabolic process
GO:0035383 thioester metabolic process
GO:0035384 thioester biosynthetic process
GO:0035970 peptidyl-threonine dephosphorylation
GO:0042180 cellular ketone metabolic process
GO:0042762 regulation of sulfur metabolic process
GO:0044272 sulfur compound biosynthetic process
GO:0050812 regulation of acyl-CoA biosynthetic process
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0051193 regulation of cofactor metabolic process
GO:0051196 regulation of coenzyme metabolic process
GO:0071616 acyl-CoA biosynthetic process
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004722 protein serine/threonine phosphatase activity
GO:0004741 [pyruvate dehydrogenase (lipoamide)] phosphatase activity
GO:0016791 phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1430728: Metabolism
R-HSA-70268: Pyruvate metabolism
R-HSA-71406: Pyruvate metabolism and Citric Acid (TCA) cycle
R-HSA-204174: Regulation of pyruvate dehydrogenase (PDH) complex
R-HSA-1428517: The citric acid (TCA) cycle and respiratory electron transport
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PDP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PDP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PDP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0710.837
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1150.951
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.20.875
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0630.845
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1030.951
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0050.998
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1010.81
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0430.979
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2620.886
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1710.874
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7430.617
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1640.0531
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PDP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PDP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PDP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PDP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PDP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PDP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PDP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPDP1
Namepyruvate dehyrogenase phosphatase catalytic subunit 1
Aliases PDP; PDH; PPM2C; protein phosphatase 2C, magnesium-dependent, catalytic subunit; PDPC; PDP 1; PDPC 1; [Pyruv ......
Chromosomal Location8q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PDP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.